7 completed, 2 terminated, 1 active not recruiting. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow merestinib: new trials by email Literature Review of merestinib trials Research Report on merestinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Merestinib on Bone Metastases in Subjects With Breast Cancer Merestinib - Bone Metastases, Breast Cancer | Phase 1 | Terminated | University of Utah | 2 | 2018-01-11 | 2021-01-08 |
| Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia Merestinib, LY2874455 - Relapsed Adult Acute Myeloid Leukemia, Refractory Adult Acute Myeloid Leukemia | Phase 1 | Completed | Jacqueline Garcia, MD | 16 | 2017-08-10 | 2020-06-30 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer Merestinib, Cisplatin, Gemcitabine - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 19 | 2017-02-03 | 2020-05-19 |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Merestinib - Carcinoma, Non-Small-Cell Lung, Solid Tumor | Phase 2 | Terminated | Dana-Farber Cancer Institute | 12 | 2016-11-11 | 2024-04-11 |
| A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Ramucirumab, Merestinib, Abemaciclib - Advanced Cancer, Colorectal Cancer | Phase 1 | Completed | Eli Lilly and Company | 23 | 2016-10-21 | 2019-03-05 |
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors LY3300054, Ramucirumab, Abemaciclib - Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors | Phase 1 | Completed | Eli Lilly and Company | 164 | 2016-06-29 | 2024-09-27 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Ramucirumab, Merestinib, Cisplatin - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 309 | 2016-05-19 | 2026-07-22 |
| A Study of Merestinib (LY2801653) in Healthy Participants Merestinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 24 | 2016-05-01 | 2016-08-29 |
| A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children LY2801653 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 23 | 2015-02-01 | 2015-06-19 |
| A Study of LY2801653 in Advanced Cancer LY2801653, Cetuximab, Cisplatin - Cancer | Phase 1 | Completed | Eli Lilly and Company | 190 | 2009-09-09 | 2018-02-20 |
Breast Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Pancreatic Neoplasms (1)
Eli Lilly and Company (7) · Dana-Farber Cancer Institute (1) · Jacqueline Garcia, MD (1) · University of Utah (1)
United States (9) · France (3) · Belgium (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1)
Jacqueline S. Garcia, MD (1) · Mark Awad, MD (1)
PMID 23275061, PMID 29188469, PMID 30833489, PMID 32537847, PMID 33229456, PMID 34465599, PMID 34499416, PMID 34592180
2015 (2), 2016 (1)